AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01318577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Cleaning & Disinfecting Solution
Description: Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
Study NCT01318577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care Solution
Description: Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
Study NCT03361800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: oral drug, 5mg tablet given once weekly x 2 doses
Study NCT01056822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1
Description: Continue with same dose of MMF as patient was taking before randomisation
Study NCT01056822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2
Description: Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
Study NCT00762164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin 10/80 split into 4
Study NCT00762164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 milligrams
Study NCT04069234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 60 mg BID for 30 days
Study NCT04069234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75mg OD for 30 Days
Study NCT04524949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 450 μg
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide
Study NCT04524949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 1350 μg
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide
Study NCT04524949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solvent: alum hydroxide
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (full face)
Description: Prototype mask system (full face variant) with novel vent and humidification system
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (full face)
Description: Prototype mask system (full face variant) with conventional vent and humidification system
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (nasal)
Description: Prototype mask system (nasal variant) with novel vent and humidification system
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (nasal)
Description: Prototype mask system (nasal variant) with conventional vent and humidification system
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (pillows)
Description: Prototype mask system (pillows variant) with conventional vent and humidification system
Study NCT02364375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (pillows)
Description: Prototype mask system (pillows variant) with conventional vent and humidification system
Study NCT04169035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.
Description: The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
Study NCT04169035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forceps or ventouse
Description: The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body.
Study NCT02700321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIFLOW/ AIRVO
Description: Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction.
Study NCT02700321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD Face Mask
Description: Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction.
Study NCT04362241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: Prednisolone Acetate 1% ophthalmic drops
Study NCT04362241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: Prednisolone Acetate 1% ophthalmic drops
Study NCT02167698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Description: This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-tidal volume ventilation
Description: This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
Study NCT02167698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
Study NCT02167698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Description: Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy
Description: Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
Study NCT02167698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedo-analgesia titration
Study NCT02167698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedo-analgesia titration
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized early enteral nutrition
Description: Early enteral nutrition and attempt to meet calorie-protein goals
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized early enteral nutrition
Description: Early enteral nutrition and attempt to meet calorie-protein goals
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized supportive care
Description: Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized supportive care
Description: Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Assay
Description: Biomarker Assay for patients in both arms
Study NCT02167698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Assay
Description: Biomarker Assay for patients in both arms
Study NCT04375891 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: 30 Gy in 10 fractions of 3 Gy each
Study NCT04375891 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiofrequency Ablation (RFA)
Description: Radiofrequency Ablation (RFA) / Vertebral Augmentation
Study NCT00979940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80mg po given one time before PCI in cath lab.
Study NCT02677441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative management
Description: Specific standardized rehabilitation protocol under Cote et al (2010)
Study NCT02677441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
Study NCT03481400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin Gene-Related Peptide
Description: Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
Study NCT03481400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Isotonic saline
Study NCT03153592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure driven ventilation strategy
Description: Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
Study NCT03153592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation strategy
Description: 13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
Study NCT04142931 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ImmunicomAIAC
Description: filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
Study NCT01668784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01668784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study NCT03779009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)
Description: Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
Study NCT03756519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
Study NCT03756519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice to stay active and engaged in usual activities.
Description: Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
Study NCT03756519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice to stay active and engaged in usual activities.
Description: Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
Study NCT03756519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice on use of ice or heat
Description: Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
Study NCT03756519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on use of ice or heat
Description: Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
Study NCT03756519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advise regarding use of medications
Description: Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
Study NCT03756519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advise regarding use of medications
Description: Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
Study NCT03041740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfluorooctyl Bromide
Description: Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
Study NCT02575586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times.
Study NCT02575586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control-Dry Needling
Description: Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times.
Study NCT04500912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supraflex Cruz 60 Micron
Description: percutaneous coronary intervention
Study NCT04500912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultimaster Tansei 80 Micron
Description: percutaneous coronary intervention
Study NCT02684851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01971710 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community leader engagement
Description: Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
Study NCT01971710 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community days
Description: The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
Study NCT01971710 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Peer Groups
Description: Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
Study NCT03213860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China
Description: The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
Study NCT04080908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol injection
Description: Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
Study NCT05033171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Scanning
Description: 3D scanning of the rod using Artec Eva Spider type manual 3D scanner
Study NCT03933007 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine,
Description: the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)
Study NCT03933007 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: midazolam,
Description: Midazolam 1 mg
Study NCT03933007 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: Fexofenadine 120 mg
Study NCT01394016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT01394016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered intramuscularly into the buttocks in Part G only.
Study NCT03059849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Dose of adalimumab will be increased by 40mg every 2 weeks.
Study NCT03645824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Patients receive up to 4 cycles of pacritinib before allo-SCT
Study NCT04144686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Rehabilitation
Description: Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
Study NCT04144686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Rehabilitation
Description: Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
Study NCT04214821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Solution
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study NCT04214821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study NCT02345447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal-based medication
Description: Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
Study NCT02345447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqueous ethanol solution non-distinguishable from verum
Study NCT03628768 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study NCT04599244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emergency pulpotomy
Description: removal of coronal pulp
Study NCT04599244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emergency pulpotomy
Description: removal of coronal pulp
Study NCT02599571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine content cigarettes
Description: Cigarettes containing a reduced amount of nicotine
Study NCT02599571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional nicotine content cigarettes
Description: Cigarettes containing a normal amount of nicotine
Study NCT03730649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane (broccoli sprout extract)
Description: Participants will topically apply Sulforaphane for a period of time
Study NCT03730649 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UV or visible light
Description: Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
Study NCT02464696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IPS cohort only
Study NCT02464696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IPS cohort only
Study NCT02464696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: Receive high flow oxygen therapy
Study NCT02464696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Air Pressure Device
Description: Undergo NIPPV
Study NCT03865979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viz RECRUIT
Description: Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB